Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 Long-Acting Injection in Healthy Adults and Adolescents in Rwanda

NCT07548021 is registered in ClinicalTrials.gov with Medicines for Malaria Venture as lead sponsor.

NCT NCT07548021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07548021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 Long-Acting Injection in Healthy Adults and Adolescents in Rwanda
Lead sponsor
Medicines for Malaria Venture
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
March 31, 2028
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, malaria (plasmodium falciparum), malaria falciparum, malaria infection, malaria parasitaemia, malaria prevention, malaria prophylaxis